Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group
We sought information worldwide on mortality according to assigned treatment in all randomized trials that began before 1985 of adjuvant tamoxifen or cytotoxic therapy for early breast cancer (with or without regional lymph-node involvement). Coverage was reasonably complete for most countries. In 28 trials of tamoxifen nearly 4000 of 16,513 women had died, and in 40 chemotherapy trials slightly more than 4000 of 13,442 women had died. The 8106 deaths were approximately evenly distributed over years 1, 2, 3, 4, and 5+ of follow-up, with little useful information beyond year 5. Systematic overviews of the results of these trials demonstrated reductions in mortality due to treatment that were significant when tamoxifen was compared with no tamoxifen (P less than 0.0001), any chemotherapy with no chemotherapy (P = 0.003), and polychemotherapy with single-agent chemotherapy (P = 0.001). In tamoxifen trials, there was a clear reduction in mortality only among women 50 or older, for whom assignment to tamoxifen reduced the annual odds of death during the first five years by about one fifth. In chemotherapy trials there was a clear reduction only among women under 50, for whom assignment to polychemotherapy reduced the annual odds of death during the first five years by about one quarter. Direct comparisons showed that combination chemotherapy was significantly more effective than single-agent therapy, but suggested that administration of chemotherapy for 8 to 24 months may offer no survival advantage over administration of the same chemotherapy for 4 to 6 months. Because it involved several thousand women, this overview was able to demonstrate particularly clearly that both tamoxifen and cytotoxic therapy can reduce five-year mortality.
This article has been cited by other articles:
McDermott, U., Settleman, J.
(2009). Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. JCO
27: 5650-5659
[Abstract][Full Text]
Bedard, P. L., Piccart-Gebhart, M. J.
(2008). Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math!. JNCI J Natl Cancer Inst
100: 1745-1747
[Full Text]
Newman, W. G., Hadfield, K. D., Latif, A., Roberts, S. A., Shenton, A., McHague, C., Lalloo, F., Howell, S., Evans, D. G.
(2008). Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients. Clin. Cancer Res.
14: 5913-5918
[Abstract][Full Text]
O'Rourke, K.
(2007). An historical perspective on meta-analysis: dealing quantitatively with varying study results. JRSM
100: 579-582
[Full Text]
Jordan, V. C.
(2007). Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point. Cancer Epidemiol. Biomarkers Prev.
16: 2207-2209
[Full Text]
Findlay, B., Tonkin, K., Crump, M., Norris, B., Trudeau, M., Blackstein, M., Burnell, M., Skillings, J., Bowman, D., Walde, D., Levine, M., Pritchard, K. I., Palmer, M. J., Tu, D., Shepherd, L.
(2007). A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Ann Oncol
18: 1646-1651
[Abstract][Full Text]
Gonzalez-Angulo, A. M., Hennessy, B. T., Broglio, K., Meric-Bernstam, F., Cristofanilli, M., Giordano, S. H., Buchholz, T. A., Sahin, A., Singletary, S. E., Buzdar, A. U., Hortobagyi, G. N.
(2007). Trends for Inflammatory Breast Cancer: Is Survival Improving?. The Oncologist
12: 904-912
[Abstract][Full Text]
Chlebowski, R.
(2007). Lifestyle Change Including Dietary Fat Reduction and Breast Cancer Outcome. J. Nutr.
137: 233S-235S
[Full Text]
Franklin, J, Pluetschow, A, Paus, M, Specht, L, Anselmo, A-P, Aviles, A, Biti, G, Bogatyreva, T, Bonadonna, G, Brillant, C, Cavalieri, E, Diehl, V, Eghbali, H, Ferme, C, Henry-Amar, M, Hoppe, R, Howard, S, Meyer, R, Niedzwiecki, D, Pavlovsky, S, Radford, J, Raemaekers, J, Ryder, D, Schiller, P, Shakhtarina, S, Valagussa, P, Wilimas, J, Yahalom, J
(2006). Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol
17: 1749-1760
[Abstract][Full Text]
Wolff, A. C., Davidson, N. E.
(2006). Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer. JCO
24: 4949-4951
[Full Text]
Buzdar, A. U.
(2006). Topoisomerase II{alpha} Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer. JCO
24: 2409-2411
[Full Text]
Smith, B. D., Gross, C. P., Smith, G. L., Galusha, D. H., Bekelman, J. E., Haffty, B. G.
(2006). Effectiveness of radiation therapy for older women with early breast cancer.. JNCI J Natl Cancer Inst
98: 681-690
[Abstract][Full Text]
Peeters, S. T.H., Heemsbergen, W. D., Koper, P. C.M., van Putten, W. L.J., Slot, A., Dielwart, M. F.H., Bonfrer, J. M.G., Incrocci, L., Lebesque, J. V.
(2006). Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy. JCO
24: 1990-1996
[Abstract][Full Text]
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., Hudis, C., Winer, E. P.
(2006). Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA
295: 1658-1667
[Abstract][Full Text]
Vigna-Taglianti, F., Vineis, P., Liberati, A., Faggiano, F.
(2006). Quality of systematic reviews used in guidelines for oncology practice. Ann Oncol
17: 691-701
[Abstract][Full Text]
International Breast Cancer Study Group,
(2006). Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. JCO
24: 1332-1341
[Abstract][Full Text]
Hutchins, L. F., Green, S. J., Ravdin, P. M., Lew, D., Martino, S., Abeloff, M., Lyss, A. P., Allred, C., Rivkin, S. E., Osborne, C. K.
(2005). Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102. JCO
23: 8313-8321
[Abstract][Full Text]
Clines, G A, Guise, T A
(2005). Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer
12: 549-583
[Abstract][Full Text]
Du, X. L., Jones, D. V., Zhang, D.
(2005). Effectiveness of Adjuvant Chemotherapy for Node-Positive Operable Breast Cancer in Older Women. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
60: 1137-1144
[Abstract][Full Text]
Davidson, N. E., O'Neill, A. M., Vukov, A. M., Osborne, C. K., Martino, S., White, D. R., Abeloff, M. D.
(2005). Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node-Positive, Steroid Hormone Receptor-Positive Breast Cancer: Results From INT 0101 (E5188). JCO
23: 5973-5982
[Abstract][Full Text]
Simmonds, M. C, Higginsa, J. P T, Stewartb, L. A, Tierneyb, J. F, Clarke, M. J, Thompson, S. G
(2005). Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials
2: 209-217
[Abstract]
Colditz, G. A.
(2005). Epidemiology and Prevention of Breast Cancer. Cancer Epidemiol. Biomarkers Prev.
14: 768-772
[Full Text]
Hamilton, A., Hortobagyi, G.
(2005). Chemotherapy: What Progress in the Last 5 Years?. JCO
23: 1760-1775
[Full Text]
Jones, K. L, Buzdar, A. U
(2004). A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer
11: 391-406
[Abstract][Full Text]
Tsao, A. S., Kim, E. S., Hong, W. K.
(2004). Chemoprevention of Cancer. CA Cancer J Clin
54: 150-180
[Abstract][Full Text]
Baum, M.
(2004). Commentary: False premises, false promises and false positives--the case against mammographic screening for breast cancer. Int J Epidemiol
33: 66-67
[Full Text]
Goldhirsch, A., Colleoni, M., Domenighetti, G., Gelber, R. D.
(2003). Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol
14: 1212-1214
[Abstract][Full Text]
Schmid, M., Jakesz, R., Samonigg, H., Kubista, E., Gnant, M., Menzel, C., Seifert, M., Haider, K., Taucher, S., Mlineritsch, B., Steindorfer, P., Kwasny, W., Stierer, M., Tausch, C., Fridrik, M., Wette, V., Steger, G., Hausmaninger, H.
(2003). Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6. JCO
21: 984-990
[Abstract][Full Text]
Du, X. L., Key, C. R., Osborne, C., Mahnken, J. D., Goodwin, J. S.
(2003). Discrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer. ANN INTERN MED
138: 90-97
[Abstract][Full Text]
Jakesz, R., Hausmaninger, H., Kubista, E., Gnant, M., Menzel, C., Bauernhofer, T., Seifert, M., Haider, K., Mlineritsch, B., Steindorfer, P., Kwasny, W., Fridrik, M., Steger, G., Wette, V., Samonigg, H.
(2002). Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. JCO
20: 4621-4627
[Abstract][Full Text]
Du, X. L., Osborne, C., Goodwin, J. S.
(2002). Population-Based Assessment of Hospitalizations for Toxicity From Chemotherapy in Older Women With Breast Cancer. JCO
20: 4636-4642
[Abstract][Full Text]
Bachleitner-Hofmann, T., Pichler-Gebhard, B., Rudas, M., Gnant, M., Taucher, S., Kandioler, D., Janschek, E., Dubsky, P., Roka, S., Sporn, E., Jakesz, R.
(2002). Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen. Clin. Cancer Res.
8: 3427-3432
[Abstract][Full Text]
Arriagada, R., Spielmann, M., Koscielny, S., Le Chevalier, T., Delozier, T., Ducourtieux, M., Tursz, T., Hill, C.
(2002). Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol
13: 1378-1386
[Abstract][Full Text]
Hortobagyi, G. N.
(2002). The Influence of Menstrual Cycle Phase on Surgical Treatment of Primary Breast Cancer: Have We Made Any Progress Over the Past 13 Years?. JNCI J Natl Cancer Inst
94: 641-643
[Full Text]
Harlan, L. C., Abrams, J., Warren, J. L., Clegg, L., Stevens, J., Ballard-Barbash, R.
(2002). Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians. JCO
20: 1809-1817
[Abstract][Full Text]
Chalmers, I., Hedges, L. V., Cooper, H.
(2002). A Brief History of Research Synthesis. Eval Health Prof
25: 12-37
[Abstract]
Stewart, L. A., Tierney, J. F.
(2002). To IPD or not to IPD?: Advantages and Disadvantages of Systematic Reviews Using Individual Patient Data. Eval Health Prof
25: 76-97
[Abstract]
Egger, M., Ebrahim, S., Smith, G. D.
(2002). Where now for meta-analysis?. Int J Epidemiol
31: 1-5
[Full Text]
Hortobagyi, G. N
(2001). Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. J Natl Cancer Inst Monogr
2001: 72-79
[Abstract][Full Text]
Campbell, M J, Woodside, J V, Secker-Walker, J, Titcomb, A, Leathem, A J C
(2001). IGF status is altered by tamoxifen in patients with breast cancer. Mol. Pathol.
54: 307-310
[Abstract][Full Text]
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Senn, H.-J.
(2001). Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. JCO
19: 3817-3827
[Full Text]
Hortobagyi, G. N.
(2001). Adjuvant Systemic Therapy for Early Breast Cancer: Progress and Controversies. Clin. Cancer Res.
7: 1839-1842
[Full Text]
Baum, M., Welch, H G., Reynolds, T M, Wierzbicki, A S, Threlfall, A. G, Collins, S., Woodman, C. B J, Coleman, M. P, Stockton, D., Babb, P., Richards, M.
(2000). Survival and reduction in mortality from breast cancer. BMJ
321: 1470a-1470
[Full Text]
Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Romeo, D., Sismondi, P., Giai, M., Genta, F., Pacini, P., Distante, V., Bolognesi, A., Aldrighetti, D., Farris, A.
(2000). Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor-Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial. JCO
18: 2718-2727
[Abstract][Full Text]
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., Cairncross, J. G.
(2000). Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology
54: 1886-1893
[Full Text]
Chu, K. C., Tarone, R. E., Brawley, O. W.
(1999). Breast Cancer Trends of Black Women Compared With White Women. Arch Fam Med
8: 521-528
[Abstract][Full Text]
Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C.
(1999). Effects of the Antiestrogen EM-800 (SCH 57050) and Cyclophosphamide Alone and in Combination on Growth of Human ZR-75-1 Breast Cancer Xenografts in Nude Mice. Cancer Res.
59: 5176-5180
[Abstract][Full Text]
von Minckwitz, G., Costa, S. D., Eiermann, W., Blohmer, J.-U., Tulusan, A. H., Jackisch, C., Kaufmann, M.
(1999). Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and Docetaxel. JCO
17: 1999-1999
[Abstract][Full Text]
Jordan, V. C., Morrow, M.
(1999). Tamoxifen, Raloxifene, and the Prevention of Breast Cancer. Endocr. Rev.
20: 253-278
[Abstract][Full Text]
Jakesz, R., Hausmaninger, H., Haider, K., Kubista, E., Samonigg, H., Gnant, M., Manfreda, D., Tschurtschenthaler, G., Kolb, R., Stierer, M., Fridrik, M., Mlineritsch, B., Steindorfer, P., Mittlbock, M., Steger, G.
(1999). Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node-Positive Breast Cancer. JCO
17: 1701-1701
[Abstract][Full Text]
Hebert-Croteau, N., Brisson, J., Latreille, J., Gariepy, G., Blanchette, C., Deschenes, L.
(1999). Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer. JCO
17: 1458-1458
[Abstract][Full Text]
Clarke, M. J
(1998). Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ
317: 1246-1248
[Full Text]
Esteva, F. J., Hortobagyi, G. N.
(1998). Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. The Oncologist
3: 300-313
[Abstract][Full Text]
Macgregor, J. I., Jordan, V. C.
(1998). Basic Guide to the Mechanisms of Antiestrogen Action. Pharmacol. Rev.
50: 151-196
[Abstract][Full Text]
Early Breast Cancer Trialists' Collaborative Group,
(1995). Effects of Radiotherapy and Surgery in Early Breast Cancer -- An Overview of the Randomized Trials. NEJM
333: 1444-1456
[Abstract][Full Text]
Garg, R., Yusuf, S., the Collaborative Group on ACE Inhibitor Trials, , Bussmann, W. D., Sleight, P., Uprichard, A., Massie, B., McGrath, B., Nilsson, B., Pitt, B., Magnani, B., Maskin, C., Ambrosioni, E., Rucinska, E., Kleber, F. X., Jennings, G., Tognoni, G., Drexler, H., Cleland, J. G. F., Franciosa, J. A., Remes, J., Swedberg, K., Swedberg, K., Dickstein, K., Maass, L., Pfeffer, M., Creager, M. A., Gordon, M., Joy, M., Sharpe, N., Sleight, P., Desche, P., McGarry, R., Collins, R., Chrysant, S. G., Cicchetti, V., Bussmann, W. D.
(1995). Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure. JAMA
273: 1450-1456
[Abstract]
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., Ballow, A. C., Frei, E., Henderson, I. C.
(1994). Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. NEJM
330: 1253-1259
[Abstract][Full Text]
Teo, K. K., Yusuf, S., Furberg, C. D.
(1993). Effects of Prophylactic Antiarrhythmic Drug Therapy in Acute Myocardial Infarction: An Overview of Results From Randomized Controlled Trials. JAMA
270: 1589-1595
[Abstract]
Henderson, B., Ross, R., Pike, M.
(1993). Hormonal chemoprevention of cancer in women. Science
259: 633-638
[Abstract]
Johnson, H. Jr, Masood, S., Belluco, C., Abou-Azama, A.-M., Dee, S., Kahn, L., Wise, L.
(1992). Prognostic Factors in Node-Negative Breast Cancer. Arch Surg
127: 1386-1391
[Abstract]
Love, R. R., Surawicz, T. S., Williams, E. C.
(1992). Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy. Arch Intern Med
152: 317-320
[Abstract]
Diener-West, M., Hawkins, B. S., Markowitz, J. A., Schachat, A. P.
(1992). A Review of Mortality From Choroidal Melanoma: II. A Meta-Analysis of 5-Year Mortality Rates Following Enucleation, 1966 Through 1988. Arch Ophthalmol
110: 245-250
[Abstract]
Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., DeMets, D. L.
(1991). Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women. ANN INTERN MED
115: 860-864
[Abstract]
Love, R. R., Cameron, L., Connell, B. L., Leventhal, H.
(1991). Symptoms Associated With Tamoxifen Treatment in Postmenopausal Women. Arch Intern Med
151: 1842-1847
[Abstract]
Richards, M.A.
(1991). Systemic Treatment of Breast Cancer. The Journal of the Royal Society for the Promotion of Health
111: 141-145
Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H. A.
(1991). Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials. JAMA
266: 93-98
[Abstract]
Gelber, R. D., Goldhirsch, A., Cavalli, F.
(1991). Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. ANN INTERN MED
114: 621-628
[Abstract]
Colditz, G. A., Stampfer, M. J., Willett, W. C., Hennekens, C. H., Rosner, B., Speizer, F. E.
(1990). Prospective Study of Estrogen Replacement Therapy and Risk of Breast Cancer in Postmenopausal Women. JAMA
264: 2648-2653
[Abstract]
Pritchard, K. I.
(1989). Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?. ANN INTERN MED
111: 1-4
[Abstract]
(1989). ADJUVANT THERAPY FOR EARLY BREAST CANCER REDUCES MORTALITY. JWatch General
1989: 1-1
[Full Text]
